Abstract: The present invention relates to a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient (“API”) which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound.

Abstract: The present invention concerns a dosage form, preferably for immediate release, comprising siponimod, a moisture-protective-agent and further pharmaceutical excipients and methods for producing said dosage form.

Abstract: The present invention relates to siponimod (BAB312) for use in the treatment of an autoimmune disease, wherein an immediate release dosage form is administered once daily to a patient as maintenance regimen and wherein the patient has experienced a specific titration regimen with siponimod beforehand.

Abstract: A method for manufacturing a spectacle lens including a lens substrate and at least one coating is disclosed. The method includes at least the following steps of providing a lens substrate comprising an uncoated or precoated front surface and an uncoated or precoated back surface, covering at least one of the surfaces of the lens substrate partially or completely with at least one coating composition, drying and/or precuring the at least one coating composition, contacting the surface of the at least one coating composition with at least one mechanical means, curing and/or hardening the at least one coating composition and obtaining a spectacle lens comprising a lens substrate and at least one coating, the surface topography of the at least one coating being modified by the at least one mechanical means.

Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.

Abstract: The present invention relates to a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient (“API”) which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound.

Abstract: The present invention relates to improved compounds for use in the treatment of diseases or conditions where the removal of senescent cells, scarred cells, and/or cancerous cells is beneficial, for example cancer. The invention also relates to methods of treating an individual suffering, or suspected of suffering, from a disease or condition wherein the removal of senescent cells, scarred cells, and/or cancerous cells is beneficial.

Abstract: An apparatus and sensing system wherein the apparatus comprises: sensing means configured to sense a parameter; optical output means configured to provide an optical output signal indicative of data obtained by the sensing means; optical input means configured to receive an optical input signal and convert the optical input signal to electrical power; and storage means configured to store the electrical power obtained by the optical input means and enable the power to be provided to the sensing means and the optical output means; and wherein the optical output means comprises one or more light emitting diodes and optical coupling means where the optical coupling means are configured to couple the apparatus to a processing device to enable data obtained by the sensing means to be transmitted to the processing device.

Abstract: A method of producing a spectacle lens includes providing a substrate having a front surface and a back surface and coating or covering at least one of the front surface or the back surface of the substrate, in full or in part, with a layer. The surface topography of the substrate surface is changed by bringing the surface into contact with a medium and the medium is removed. A product made according to the method and including (i) a spectacle lens or (ii) a representation of the spectacle lens in the form of computer-readable data present on a data medium or (iii) a data medium including a virtual representation of the spectacle lens in the form of computer-readable data or (iv) a representation of the spectacle lens in the form of a computer-readable data signal, is also disclosed.

Abstract: A method for manufacturing a spectacle lens having a lens substrate and at least one coating is disclosed. The method includes providing a lens substrate having an uncoated or precoated front surface and an uncoated or precoated back surface, applying at least one coating to at least one of the surfaces of the lens substrate, the surface of the at least one coating being modifiable when contacted with at least one medium able to modify the surface of the at least one coating, contacting the surface of the at least one coating, partially or completely, with the at least one medium, considering the individual peripheral refraction, obtaining the spectacle lens having the lens substrate and the at least one coating, the surface of the at least one coating being modified according to the individual peripheral refraction.

Abstract: A method of manufacturing a spectacle lens having a lens substrate a lens substrate and at least one coating is disclosed. The method includes at least the following steps in the given order: providing a lens substrate having an uncoated or pre-coated front surface and an uncoated or pre-coated back surface, coating at least one surface with at least one coating, the surface of the at least one coating being modifiable when contacted with at least one medium being able to modify the surface of the coating, completely or partially contacting the surface of the coating with the at least one medium, applying at least one single electromagnetic pulse to at least one of the surfaces of the spectacle lens having the lens substrate, the coating and the medium and obtaining the spectacle lens having the at least one coating with a completely or partially modified surface.

Abstract: A method of manufacturing a spectacle lens having a lens substrate a lens substrate and at least one coating is disclosed. The method includes at least the following steps in the given order: providing a lens substrate having an uncoated or pre-coated front surface and an uncoated or pre-coated back surface, coating at least one surface with at least one coating, the surface of the at least one coating being modifiable when contacted with at least one medium being able to modify the surface of the coating, completely or partially contacting the surface of the coating with the at least one medium, applying at least one single electromagnetic pulse to at least one of the surfaces of the spectacle lens having the lens substrate, the coating and the medium and obtaining the spectacle lens having the at least one coating with a completely or partially modified surface.

Abstract: A method for manufacturing a spectacle lens having a lens substrate and at least one coating is disclosed. The method includes providing a lens substrate having an uncoated or precoated front surface and an uncoated or precoated back surface, applying at least one coating to at least one of the surfaces of the lens substrate, the surface of the at least one coating being modifiable when contacted with at least one medium able to modify the surface of the at least one coating, contacting the surface of the at least one coating, partially or completely, with the at least one medium, considering the individual peripheral refraction, obtaining the spectacle lens having the lens substrate and the at least one coating, the surface of the at least one coating being modified according to the individual peripheral refraction.

Abstract: A method for manufacturing a spectacle lens including a lens substrate and at least one coating is disclosed. The method includes at least the following steps of providing a lens substrate comprising an uncoated or precoated front surface and an uncoated or precoated back surface, covering at least one of the surfaces of the lens substrate partially or completely with at least one coating composition, drying and/or precuring the at least one coating composition, contacting the surface of the at least one coating composition with at least one mechanical means, curing and/or hardening the at least one coating composition and obtaining a spectacle lens comprising a lens substrate and at least one coating, the surface topography of the at least one coating being modified by the at least one mechanical means.

Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.

Abstract: A kit, system and method for the detection of a pathogen, in particular SARS-CoV-2, by surface enhanced Raman spectroscopy (SERS) obtained from a sample brought into contact with non-magnetic native metal nanoparticles. The kit includes the non-magnetic native metal nanoparticles and a software designed to detect the presence of the pathogen in the sample.

Abstract: The present invention relates to improved compounds for use in the treatment of diseases or conditions where the removal of senescent cells, scarred cells, and/or cancerous cells is beneficial, for example cancer. The invention also relates to methods of treating an individual suffering, or suspected of suffering, from a disease or condition wherein the removal of senescent cells, scarred cells, and/or cancerous cells is beneficial.

Abstract: A method of producing a spectacle lens includes providing a substrate having a front surface and a back surface and coating or covering at least one of the front surface or the back surface of the substrate, in full or in part, with a layer. The surface topography of the substrate surface is changed by bringing the surface into contact with a medium and the medium is removed. A product made according to the method and including (i) a spectacle lens or (ii) a representation of the spectacle lens in the form of computer-readable data present on a data medium or (iii) a data medium including a virtual representation of the spectacle lens in the form of computer-readable data or (iv) a representation of the spectacle lens in the form of a computer-readable data signal, is also disclosed.

Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.

Abstract: The present invention relates to a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient (“API”) which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound.